DGAP-Adhoc
Merck KGaA: Merck to Acquire Sigma-Aldrich to Enhance Position in Attractive Life Science Industry
Merck KGaA / Key word(s): Offer
22.09.2014 11:56
Dissemination of an Ad hoc announcement according to § 15 WpHG, transmitted
by DGAP - a service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Anzeige
Merck, a leading company for innovative and top-quality high-tech products
in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich
Corporation ("Sigma-Aldrich"), today have entered into a definitive
agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion
(EUR13.1 billion), establishing one of the leading players in the $130
billion global life science industry.
Merck will acquire all of the outstanding shares of Sigma-Aldrich for $140
per share in cash. The agreed price represents a 37% premium to the latest
closing price of $102.37 on September 19, 2014, and a 36% premium to the
one-month average closing price. The transaction is expected to be
immediately accretive to Merck's EPS pre and EBITDA margin. Merck expects
to achieve annual synergies of approximately EUR260 million (approximately
$340 million), which should be fully realized within three years after
closing.
Bridge financing has been secured for the all-cash transaction, and Merck
expects the final financing structure will comprise a combination of cash
on Merck's balance sheet, bank loans and bonds. Closing is expected
mid-year 2015, subject to regulatory approvals, approval by a special
meeting of the shareholders of Sigma-Aldrich and other customary closing
conditions.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
Cautionary Note Regarding Forward-Looking Statements
This communication may include 'forward-looking statements.' Statements
that include words such as 'anticipate,' 'expect,' 'should,' 'would,'
'intend,' 'plan,' 'project,' 'seek,' 'believe,' 'will,' and other words of
similar meaning in connection with future events or future operating or
financial performance are often used to identify forward-looking
statements. All statements in this communication, other than those relating
to historical information or current conditions, are forward-looking
statements. We intend these forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements in the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
in the pharmaceutical, chemical and life science sectors, and Sigma-Aldrich
Corporation ("Sigma-Aldrich"), today have entered into a definitive
agreement under which Merck will acquire Sigma-Aldrich for $17.0 billion
(EUR13.1 billion), establishing one of the leading players in the $130
billion global life science industry.
Merck will acquire all of the outstanding shares of Sigma-Aldrich for $140
per share in cash. The agreed price represents a 37% premium to the latest
closing price of $102.37 on September 19, 2014, and a 36% premium to the
one-month average closing price. The transaction is expected to be
immediately accretive to Merck's EPS pre and EBITDA margin. Merck expects
to achieve annual synergies of approximately EUR260 million (approximately
$340 million), which should be fully realized within three years after
closing.
Bridge financing has been secured for the all-cash transaction, and Merck
expects the final financing structure will comprise a combination of cash
on Merck's balance sheet, bank loans and bonds. Closing is expected
mid-year 2015, subject to regulatory approvals, approval by a special
meeting of the shareholders of Sigma-Aldrich and other customary closing
conditions.
---------------------------------------------------------------------------
Information and Explaination of the Issuer to this News:
Cautionary Note Regarding Forward-Looking Statements
This communication may include 'forward-looking statements.' Statements
that include words such as 'anticipate,' 'expect,' 'should,' 'would,'
'intend,' 'plan,' 'project,' 'seek,' 'believe,' 'will,' and other words of
similar meaning in connection with future events or future operating or
financial performance are often used to identify forward-looking
statements. All statements in this communication, other than those relating
to historical information or current conditions, are forward-looking
statements. We intend these forward-looking statements to be covered by the
safe harbor provisions for forward-looking statements in the Private
Securities Litigation Reform Act of 1995. These forward-looking statements
Diskutieren Sie über die enthaltenen Werte
Aktuelle Themen
Weitere Artikel des Autors
1 im Artikel enthaltener WertIm Artikel enthaltene Werte